Conserved oncogenic behavior of the FAM83 family regulates MAPK signaling in human cancer

Molecular Cancer Research

Volumn 12, Issue 8, 2014, Pages 1156-1165

  Cipriano, Rocky ^a   Miskimen, Kristy L S ^a   Bryson, Benjamin L ^a   Foy, Chase R ^a   Bartel, Courtney A ^a   Jackson, Mark W ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAM83A PROTEIN; FAM83C PROTEIN; FAM83D PROTEIN; FAM83E PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN; UNCLASSIFIED DRUG; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST EPITHELIUM; CARCINOGENESIS; CARCINOGENICITY; CELL COUNT; CELL FRACTIONATION; CELL GROWTH; CELL LYSATE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; LUNG ADENOCARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MASS SPECTROMETRY; MOUSE; NONHUMAN; ONCOGENE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; UPREGULATION; WESTERN BLOTTING; ANIMAL; BREAST TUMOR; CELL TRANSFORMATION; EPITHELIUM CELL; FEMALE; GENETICS; MAMMARY GLAND; METABOLISM; NUDE MOUSE; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CARCINOGENESIS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIAL CELLS; FEMALE; HUMANS; MAMMARY GLANDS, HUMAN; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM PROTEINS; ONCOGENES; SIGNAL TRANSDUCTION;

EID: 84905979434     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-13-0289     Document Type: Article

References (18)

1. Rho O, Kim DJ, Kiguchi K, Digiovanni J. Growth factor signaling pathways as targets for prevention of epithelial carcinogenesis. Mol Carcinogenesis 2011;50:264-79.
2. Duncan JS, Whittle MC, Nakamura K, Abell AN, Midland AA, Zawistowski JS, et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 2012;149:307-21.
3. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Disco 2005;4:988-1004.
4. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007;26:3291-310. (Pubitemid 46763022)
5. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008;27:5497-510.
6. Cipriano R, Graham J, Miskimen KL, Bryson BL, Bruntz RC, Scott SA, et al. FAM83B mediates EGFR- and RAS-driven oncogenic transformation. J Clin Invest 2012;122:3197-210.
7. Lee SY, Meier R, Furuta S, Lenburg ME, Kenny PA, Xu R, et al. FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice. J Clin Invest 2012;122:3211-20.
8. Kan CE, Patton JT, Stark GR, Jackson MW. p53-mediated growth suppression in response to Nutlin-3 in cyclin D1 transformed cells occurs independently of p21. Cancer Res 2007;67:9862-8. (Pubitemid 47621234)
9. Patton JT, Mayo LD, Singhi AD, Gudkov AV, Stark GR, Jackson MW. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. Cancer Res 2006;66:3169-76.
10. Jackson MW, Agarwal MK, Agarwal ML, Agarwal A, Stanhope-Baker P, Williams BR, et al. Limited role of N-terminal phosphoserine residues in the activation of transcription by p53. Oncogene 2004;23:4477-87. (Pubitemid 38850426)
11. Simossis VA, Heringa J. PRALINE: a multiple sequence alignment toolbox that integrates homology-extended and secondary structure information. Nucleic Acids Res 2005;33:W289-94. (Pubitemid 44529928)
12. Li Y, Dong X, Yin Y, Su Y, Xu Q, Zhang Y, et al. BJ-TSA-9, a novel human tumor-specific gene, has potential as a biomarker of lung cancer. Neoplasia 2005;7:1073-80. (Pubitemid 44430986)
13. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 2007;9:166-80.
14. Balko JM, Cook RS, Vaught DB, Kuba MG, Miller TW, Bhola NE, et al. Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nat Med 2012;18:1052-9.
15. Cipriano R, Bryson BL, Miskimen KL, Bartel CA, Hernandez-Sanchez W, Bruntz RC, et al. Hyperactivation of EGFR and downstreameffector phospholipase D1 by oncogenic FAM83B. Oncogene 2013 Aug 5. [Epub ahead of print].
16. Cipriano R, Miskimen KL, Bryson BL, Foy CR, Bartel CA, Jackson MW. FAM83B-mediated activation of PI3K/AKT and MAPK signaling cooperates to promote epithelial cell transformation and resistance to targeted therapies. Oncotarget 2013;4:729-38.
17. Liu L, Liao GQ, He P, Zhu H, Liu PH, Qu YM, et al. Detection of circulating cancer cells in lung cancer patients with a panel of marker genes. Biochem Biophys Res Commun 2008;372:756-60.
18. Santamaria A, Nagel S, Sillje HH, Nigg EA. The spindle protein CHICA mediates localization of the chromokinesin KID to the mitotic spindle. Curr Biol 2008;18:723-9.